216 related articles for article (PubMed ID: 37324233)
1. Thyroid Receptor Antibody and the Development of Graves' Orbitopathy: Clinical Experience of using Radioiodine Ablation in the Management of Graves' Orbitopathy in post-iodine ablation hypothyroid patient.
Christina E; Budiawan H; Indrawati H; Affandi Soeriadi E; Nugrahadi T; Kartamihardja AH
Asia Ocean J Nucl Med Biol; 2023; 11(2):185-190. PubMed ID: 37324233
[TBL] [Abstract][Full Text] [Related]
2. Radioactive iodine treatment for Graves' hyperthyroidism: incidence of Graves orbitopathy.
Quah NQX; Sobti MM; Wren AM; Scawn R; Kalogianni E; Cleland J; Maenhout A
Nucl Med Commun; 2024 Feb; 45(2):103-107. PubMed ID: 37982569
[TBL] [Abstract][Full Text] [Related]
3. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
Woo YJ; Jang SY; Lim TH; Yoon JS
Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
[TBL] [Abstract][Full Text] [Related]
4. The Role of the Microbiota in Graves' Disease and Graves' Orbitopathy.
Hou J; Tang Y; Chen Y; Chen D
Front Cell Infect Microbiol; 2021; 11():739707. PubMed ID: 35004341
[TBL] [Abstract][Full Text] [Related]
5. Serum thyroglobulin is associated with orbitopathy in Graves' disease.
Khamisi S; Lundqvist M; Emadi P; Almby K; Ljunggren Ö; Karlsson FA
J Endocrinol Invest; 2021 Sep; 44(9):1905-1911. PubMed ID: 33515213
[TBL] [Abstract][Full Text] [Related]
6. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.
De Bellis A; Conzo G; Cennamo G; Pane E; Bellastella G; Colella C; Iacovo AD; Paglionico VA; Sinisi AA; Wall JR; Bizzarro A; Bellastella A
Endocrine; 2012 Apr; 41(2):320-6. PubMed ID: 22169963
[TBL] [Abstract][Full Text] [Related]
7. Radioiodine thyroid ablation in graves' hyperthyroidism: merits and pitfalls.
Nwatsock JF; Taieb D; Tessonnier L; Mancini J; Dong-A-Zok F; Mundler O
World J Nucl Med; 2012 Jan; 11(1):7-11. PubMed ID: 22942775
[TBL] [Abstract][Full Text] [Related]
8. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.
Kahaly GJ; Bartalena L; Hegedüs L; Leenhardt L; Poppe K; Pearce SH
Eur Thyroid J; 2018 Aug; 7(4):167-186. PubMed ID: 30283735
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effect of low-dose radioiodine ablation for Graves' orbitopathy: results of a retrospective study.
Lanzolla G; Menconi F; Nicolì F; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
J Endocrinol Invest; 2021 Dec; 44(12):2575-2579. PubMed ID: 33844165
[TBL] [Abstract][Full Text] [Related]
10. The role and molecular mechanism of gut microbiota in Graves' orbitopathy.
Li Y; Luo B; Tong B; Xie Z; Cao J; Bai X; Peng Y; Wu Y; Wang W; Qi X
J Endocrinol Invest; 2023 Feb; 46(2):305-317. PubMed ID: 35986869
[TBL] [Abstract][Full Text] [Related]
11. Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients.
Leo M; Sabini E; Ionni I; Sframeli A; Mazzi B; Menconi F; Molinaro E; Bianchi F; Brozzi F; Santini P; Elisei R; Nardi M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2018 Mar; 41(3):357-361. PubMed ID: 28856610
[TBL] [Abstract][Full Text] [Related]
12. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
[TBL] [Abstract][Full Text] [Related]
13. Modulating gut microbiota in a mouse model of Graves' orbitopathy and its impact on induced disease.
Moshkelgosha S; Verhasselt HL; Masetti G; Covelli D; Biscarini F; Horstmann M; Daser A; Westendorf AM; Jesenek C; Philipp S; Diaz-Cano S; Banga JP; Michael D; Plummer S; Marchesi JR; Eckstein A; Ludgate M; Berchner-Pfannschmidt U;
Microbiome; 2021 Feb; 9(1):45. PubMed ID: 33593429
[TBL] [Abstract][Full Text] [Related]
14. Thyrotropin receptor antibodies and Graves' orbitopathy.
Diana T; Ponto KA; Kahaly GJ
J Endocrinol Invest; 2021 Apr; 44(4):703-712. PubMed ID: 32749654
[TBL] [Abstract][Full Text] [Related]
15. Current concepts regarding Graves' orbitopathy.
Bartalena L; Tanda ML
J Intern Med; 2022 Nov; 292(5):692-716. PubMed ID: 35604323
[TBL] [Abstract][Full Text] [Related]
16. Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy.
Ryder M; Wentworth M; Algeciras-Schimnich A; Morris JC; Garrity J; Sanders J; Young S; Sanders P; Furmaniak J; Rees Smith B
Thyroid; 2021 Oct; 31(10):1597-1602. PubMed ID: 34114495
[No Abstract] [Full Text] [Related]
17. Management of Graves' hyperthyroidism: present and future.
Bartalena L; Piantanida E; Gallo D; Ippolito S; Tanda ML
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):153-166. PubMed ID: 35287535
[TBL] [Abstract][Full Text] [Related]
18. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
19. Is Recombinant Human TSH a Trigger for Graves' Orbitopathy?
Daumerie C; Boschi A; Perros P
Eur Thyroid J; 2012 Jul; 1(2):105-9. PubMed ID: 24783004
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of Graves' Orbitopathy and Graves' Hyperthyroidism after a Trauma to the Eye.
Sabini E; Ionni I; Rocchi R; Vitti P; Marcocci C; Marinò M
Eur Thyroid J; 2018 Jan; 7(1):51-54. PubMed ID: 29594055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
